SAN DIEGO, May 29 /PRNewswire-FirstCall/ -- Bridgetech Holdings International, Inc. , a company focused on maximizing the potential of emerging healthcare products and services in the U.S. and Asian markets, today announced that it has signed a strategic alliance agreement with ValiRx plc, a biopharmaceutical company based in England. The agreement governs cooperative efforts in creating and exploiting market and technology transfer initiatives between Europe and Greater China.
“Bridgetech’s ability to excel in the marketplace is, in no small part, thanks to our prestigious set of global alliance partners. ValiRx is one of the European industry leaders in cancer therapeutics and diagnostics,” stated Michael Chermak, Chairman and CEO of Bridgetech. “We seek to identify innovative oncology products that fit our Greater China market strategy.”
Dr. Satu Vainikka, CEO of ValiRx, said “We are experienced in successful transferring of technologies and products into the commercial endpoints. ValiRx is excited to execute this alliance agreement with Bridgetech to accelerate the process of taking knowledge generated in laboratories and turning them into market-ready products.”
Tony Moore, Chairman of ValiRx Plc and MCC global said “MCC is delighted that following the recent strategic agreement between Bridgetech and MCC, we have been able to facilitate the introduction that has led to this alliance.”
About Bridgetech Holdings International, Inc.
Bridgetech is leveraging its extensive network of relationships in China and the U.S. to capitalize on the demand for Western healthcare in Greater China. The company is bringing emerging drugs, devices and diagnostics to Greater China, with an initial focus on oncology. For additional information, please visit Bridgetech at www.bthi.com.
About ValiRx Plc
ValiRx Plc is a biopharmaceutical development company that is building a portfolio of complementary cancer-related therapeutic and diagnostic technologies. It currently holds stakes in Cronos and Morphogenesis Inc; * Cronos holds licenses to two innovative and potentially market changing technologies, GeneICE and HyperGenomics; * Morphogenesis Inc. is developing a portfolio of cell therapy products for the treatment of chronic disorders. Its most advanced product, being ImmuneFx(tm) for which it recently received a patent from the US patent office. ValiRx Plc was created and advised on its listing on the London Stock Exchange’s Alternative Investment Market (VAL) by MCC Global (www.mccglobal.com). For additional information, please visit ValiRx at www.valirx.com
Forward-Looking Statements.
Statements contained in this press release that are not statements of historical fact are “forward-looking statements” as that term is defined under federal securities laws, including, without limitation, all statements concerning expectations, beliefs, goals, intention or strategies for the future of Bridgetech. Forward-looking statements may be identified by words such as “goals,” “plans,” “believes,” “will,” “expects” and other words of similar meaning used in conjunction with, among other things, discussions of future operations, financial performance, product development and new ventures. Many factors could cause actual events or results to differ materially from those expressed in any forward-looking statement. Investors are cautioned not to place any undue reliance on any forward-looking statements.
Contacts: Media Relations: Vince Heald, Beck Ellman Heald -- 858-453-9600 vheald@behmedia.com. www.beckellmanheald.com Investor Relations: Redwood Consultants, LLC -- 415-884-0348
Bridgetech Holdings International, Inc.
CONTACT: Media Relations, Vince Heald of Beck Ellman Heald,+1-858-453-9600, vheald@behmedia.com; or Investor Relations, RedwoodConsultants, LLC, +1-415-884-0348, both for Bridgetech HoldingsInternational, Inc.
